by Jen Hodson | Nov 13, 2019 | Articles
.post-meta {display:none;} BioWorld MedTech By Meg Bryant Nanthealth Inc. has received U.S. FDA clearance for a whole exome sequencing test to determine overall tumor mutational burden (TMB) in cancer tissue. Known as Omics Core, the first-of-its-kind in vitro...
by Jen Hodson | Jun 12, 2018 | Articles, Press Releases
7:02 pm MST | Jun 8, 2018 | BioCentury | Product Development POC FOR CYTOKINES Cytokines are emerging as a logical combination partner to boost PD-1 responses by Emily Cukier, Senior Writer Download Article...
by Jen Hodson | Jun 12, 2017 | Articles
FALSE REPORTING While it is not befitting for us to dignify false reporting or be distracted by false claims, both an online health trade publication and an online political publication, published articles containing numerous inaccuracies. Letters we wrote to these...
by Jen Hodson | Feb 24, 2017 | Articles
Medicine's Manhattan Project The WorldPost/The Huffington Post by Dr. Patrick Soon Shiong Download...
by Jen Hodson | Feb 23, 2017 | Articles
Redefining Cancer A Conversation With Patrick Soon-Shiong, MD, FRCS(C), FACS By Jo Cavallo Download...
by Jen Hodson | Jan 4, 2017 | Articles
Scene Magazine – Sue Cullen January 1, 2017 In the battle against cancer, patients and physicians now have available a new, unique molecular test that can predict whether a particular cancer will respond to chemotherapy, targeted therapy, or immunotherapy before a...
